Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Florence Duffaud

Showing results (111-120 of 132) with videos related to

Pageof 14
Sort By:
The Oncologist|July 30, 2017
Activity of Pazopanib and Trabectedin in Advanced Alveolar Soft Part SarcomaSilvia Stacchiotti, Olivier Mir, Axel Le Cesne, et al.
European Journal of Cancer (Oxford, England : 1990)|February 20, 2026
Natural history and treatment sensitivity of alveolar soft part sarcoma: A national multicenter analysis from the French sarcoma groupEva Kalfala, Alexandra Meurgey, Clémence Hénon, et al.
Bulletin Du Cancer|November 4, 2005
[Recommendations for the management of GIST patients]Jean-Yves Blay, Bruno Landi, Sylvie Bonvalot, et al.
The Lancet. Oncology|August 10, 2024
Discontinuation versus continuation of imatinib in patients with advanced gastrointestinal stromal tumours (BFR14): exploratory long-term follow-up of an open-label, multicentre, randomised, phase 3 trialJean-Yves Blay, Quentin Devin, Florence Duffaud, et al.
BMC Cancer|February 14, 2020
Development of a disease-specific graded prognostic assessment index for the management of sarcoma patients with brain metastases (Sarcoma-GPA)Anna Patrikidou, Loic Chaigneau, Nicolas Isambert, et al.
Cancers|January 21, 2023
Distinct Cellular Origins and Differentiation Process Account for Distinct Oncogenic and Clinical Behaviors of LeiomyosarcomasElodie Darbo, Gaëlle Pérot, Lucie Darmusey, et al.
JAMA Surgery|April 3, 2020
Quality of Surgery and Outcome in Localized Gastrointestinal Stromal Tumors Treated Within an International Intergroup Randomized Clinical Trial of Adjuvant ImatinibAlessandro Gronchi, Sylvie Bonvalot, Andres Poveda Velasco, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 18, 2015
Time to Definitive Failure to the First Tyrosine Kinase Inhibitor in Localized GI Stromal Tumors Treated With Imatinib As an Adjuvant: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Intergroup Randomized Trial in Collaboration With the Australasian Gastro-Intestinal Trials Group, UNICANCER, French Sarcoma Group, Italian Sarcoma Group, and Spanish Group for Research on SarcomasPaolo G Casali, Axel Le Cesne, Andres Poveda Velasco, et al.
European Journal of Cancer (Oxford, England : 1990)|June 16, 2026
A pooled analysis of phase 2 clinical trials in advanced chordomaGregory M Cote, Corrine F Elliott, Astrid Lipplaa, et al.
Cancer|March 5, 2020
Doxorubicin plus dacarbazine, doxorubicin plus ifosfamide, or doxorubicin alone as a first-line treatment for advanced leiomyosarcoma: A propensity score matching analysis from the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma GroupLorenzo D'Ambrosio, Nathan Touati, Jean-Yves Blay, et al.
Pageof 14

Showing results (111-120 of 132) with videos related to

Sort By:
Pageof 14
The Oncologist|July 30, 2017
Activity of Pazopanib and Trabectedin in Advanced Alveolar Soft Part SarcomaSilvia Stacchiotti, Olivier Mir, Axel Le Cesne, et al.
European Journal of Cancer (Oxford, England : 1990)|February 20, 2026
Natural history and treatment sensitivity of alveolar soft part sarcoma: A national multicenter analysis from the French sarcoma groupEva Kalfala, Alexandra Meurgey, Clémence Hénon, et al.
Bulletin Du Cancer|November 4, 2005
[Recommendations for the management of GIST patients]Jean-Yves Blay, Bruno Landi, Sylvie Bonvalot, et al.
The Lancet. Oncology|August 10, 2024
Discontinuation versus continuation of imatinib in patients with advanced gastrointestinal stromal tumours (BFR14): exploratory long-term follow-up of an open-label, multicentre, randomised, phase 3 trialJean-Yves Blay, Quentin Devin, Florence Duffaud, et al.
BMC Cancer|February 14, 2020
Development of a disease-specific graded prognostic assessment index for the management of sarcoma patients with brain metastases (Sarcoma-GPA)Anna Patrikidou, Loic Chaigneau, Nicolas Isambert, et al.
Cancers|January 21, 2023
Distinct Cellular Origins and Differentiation Process Account for Distinct Oncogenic and Clinical Behaviors of LeiomyosarcomasElodie Darbo, Gaëlle Pérot, Lucie Darmusey, et al.
JAMA Surgery|April 3, 2020
Quality of Surgery and Outcome in Localized Gastrointestinal Stromal Tumors Treated Within an International Intergroup Randomized Clinical Trial of Adjuvant ImatinibAlessandro Gronchi, Sylvie Bonvalot, Andres Poveda Velasco, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 18, 2015
Time to Definitive Failure to the First Tyrosine Kinase Inhibitor in Localized GI Stromal Tumors Treated With Imatinib As an Adjuvant: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Intergroup Randomized Trial in Collaboration With the Australasian Gastro-Intestinal Trials Group, UNICANCER, French Sarcoma Group, Italian Sarcoma Group, and Spanish Group for Research on SarcomasPaolo G Casali, Axel Le Cesne, Andres Poveda Velasco, et al.
European Journal of Cancer (Oxford, England : 1990)|June 16, 2026
A pooled analysis of phase 2 clinical trials in advanced chordomaGregory M Cote, Corrine F Elliott, Astrid Lipplaa, et al.
Cancer|March 5, 2020
Doxorubicin plus dacarbazine, doxorubicin plus ifosfamide, or doxorubicin alone as a first-line treatment for advanced leiomyosarcoma: A propensity score matching analysis from the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma GroupLorenzo D'Ambrosio, Nathan Touati, Jean-Yves Blay, et al.
Pageof 14